Panuveitis following Vaccination for COVID-19

Mudie, Lucy I.; Zick, Jon; Dacey, Mark; Palestine, Alan G.

doi:10.1080/09273948.2021.1949478

Cited by 84 publications

(67 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, this is the largest case series examining RVO and AMD-related submacular hemorrhage after SARS-CoV-2 vaccination. Known ocular complications associated with vaccination include acute macular neuroretinopathy after ChADOx1 nCOV-19 vaccination [ 14 ] and central serous retinopathy, reactivation of Vogt–Koyanagi–Harada disease, panuveitis, and DMEK graft rejection after BNT162b2 vaccination [ 15 , 16 , 17 , 18 ]. No report has described RVO or AMD-related submacular hemorrhage, nor any other ocular hemorrhagic complications, after vaccination.…”

Section: Discussionmentioning

confidence: 99%

“…This increases the need for ophthalmological studies on vaccine-related side-effects, where SARS-CoV-2 vaccination may become annual. Known intraocular side-effects include acute macular neuroretinopathy, central serous chorioretinopathy, reactivation of Vogt-Koyanagi-Harada disease, panuveitis, Descemet’s membrane endothelial keratoplasty (DMEK) graft rejection, retinal hemorrhage and vascular events including retinal arterial occlusion and retinal vein occlusion (RVO) [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ]. Here, we present a unique case series of RVO, and age-related macular degeneration (AMD) exhibiting submacular hemorrhage, temporally related to administration of SARS-CoV-2 vaccines.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Retinal Hemorrhage after SARS-CoV-2 Vaccination

Park

Byun²,

Byeon

et al. 2021

JCM

View full text Add to dashboard Cite

To report retinal vein occlusion (RVO) and age-related macular degeneration (AMD)-related submacular hemorrhage developing after administration of SARS-CoV-2 vaccines, a single-center, retrospective observational case series was conducted. Clinical data including fundus photographs and optical coherence tomography (OCT) scans were reviewed. Twenty-three eyes of 21 patients were included with the median age at symptom presentation being 77 years (range: 51–85 years). Twelve eyes (52.2%) had submacular hemorrhage and 11 (47.8%) had RVO. Twelve patients (60.9%) had been vaccinated with the Pfizer vaccine (BNT162b2) and 8 with the AstraZeneca (ChAdOx1) vaccine. Sixteen patients (76.2%) experienced ocular disease exacerbation after the first vaccination and 4 (19.0%) after the second vaccination. The median visual acuity (logarithm of the minimal angle of resolution; logMAR) before symptom development was 0.76 (interquartile range: 0.27–1.23); the median logMAR at symptom presentation was 1.40 (interquartile range 0.52–1.70). The median time between vaccination and symptom exacerbation was 2.0 days (interquartile range: 1.0–3.0 days). Five patients (23.8%) underwent tests for hematological abnormalities, including the presence of anti-PF4 antibodies; all were negative. Further studies with larger patient group for evaluation of effect of SARS-CoV-2 vaccination on retinal hemorrhage are necessary.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Retinal Hemorrhage after SARS-CoV-2 Vaccination

Park

Byun²,

Byeon

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…There was no further investigation. The second case concerned a female subject who on examination was found to have panuveitis [ 53 ]. She developed symptoms 3 days after the second dose.…”

Section: Covid-19 Vaccine-associated Ocular Inflammationmentioning

confidence: 99%

The Eye of the Storm: COVID-19 Vaccination and the Eye

Betzler

Ng³

et al. 2021

Ophthalmol Ther

View full text Add to dashboard Cite

The COVID-19 pandemic has galvanized the global response towards the development of new vaccines based on novel technologies at an unprecedented pace. Since the widespread implementation of vaccination campaigns, case reports on vaccines' systemic side effects, including ocular manifestations, have emerged. Since administered vaccines are generally not able to cause the disease in the recipient, or induce an immune response against the pathogen, we hypothesize that the development of ocular phenomena post-COVID-19 vaccination may occur via an immune response elicited by the vaccine. Of many, the most common ocular adverse events include facial nerve palsy, central venous sinus thrombosis and acute anterior uveitis. These COVID-19 vaccine-induced ocular (CVIO) adverse events could resemble the ocular findings in some of the COVID-19 patients. This review will provide a comprehensive overview of published ocular side effects potentially associated with COVID-19 vaccination and serve as a springboard for further research into CVIO adverse events.

show abstract

“… 1 Since the implementation of vaccine campaigns, reports of ocular adverse effects have emerged. Although uveitis is a rare adverse event, there are reported events following various Covid-19 vaccines 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 including anterior uveitis, multiple evanescent white dot syndrome (MEWDS), acute macular neuroretinopathy, central serous retinopathy, multifocal choroidtis, and reactivation of Vogt-Koyanagi-Harada (VKH)-disease.…”

Section: Introductionmentioning

confidence: 99%

Acute-onset Vogt-Koyanagi-Harada like uveitis following Covid-19 inactivated virus vaccination

Chen

Wang

2022

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

Purpose We report a case of a 19-year-old male who presented with bilateral Vogt-Koyanagi-Harada (VKH)-like panuveitis following an injection of an inactivated Covid-19 vaccine. Observations A 19-year-old male was referred to our clinic with a 2-week history of blurred vision on both eyes and headaches, 12 hours following the administration of the first dose of an inactivated Covid-19 virus vaccine (Sinovac). He denied any past ocular or medical history. Clinical examination and multimodal imaging tests identified serous retinal detachment and choroidal thickening posteriorly and deep yellow foci in the far peripheral retina. Aqueous humor analysis ruled out viral and bacterial infection including Covid-19, but demonstrated an elevated interleukin-6 level. A workup ruled out systemic infection or autoimmune disease. Although the patient received a single positive T-SPOT result, no other clinical evidence supported active tuberculosis infection. Non-infectious panuveitis was diagnosed and treated with periocular steroids that quickly resolved the serous retinal detachment. Conclusions and Importance This is the first report of VKH-like uveitis following an inactivated Covid-19 vaccine, with aqueous humor analysis ruling out viral or bacterial infection and demonstrating an elevated interleukin-6 level. Though rare, VKH-like uveitis may be associated with administration of an inactivated Covid-19 vaccine.

show abstract

Panuveitis following Vaccination for COVID-19

Cited by 84 publications

References 5 publications

Retinal Hemorrhage after SARS-CoV-2 Vaccination

Retinal Hemorrhage after SARS-CoV-2 Vaccination

The Eye of the Storm: COVID-19 Vaccination and the Eye

Acute-onset Vogt-Koyanagi-Harada like uveitis following Covid-19 inactivated virus vaccination

Contact Info

Product

Resources

About